Actively Recruiting
Evaluating Safety and Efficacy of XER-001 with Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
Led by Xerient Pharma · Updated on 2026-08-17
36
Participants Needed
5
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of XER-001, a drug delivered through the nasoduodenal route, in combination with stereotactic body radiotherapy SBRT for patients with locally advanced pancreatic cancer LAPC. This phase 1 and phase 2a study aims to identify the best dose of XER-001 and assess safety and efficacy when combined with SBRT, including the effects of more flexible duodenal radiation dose limits. Participants will receive increasing doses of XER-001 alongside SBRT. The phase 1 portion focuses on safety, tolerability, and pharmacokinetics of XER-001 with SBRT, while phase 2a evaluates safety and treatment effectiveness with adjusted radiation dose constraints. The treatment involves nasoduodenal drug administration and precise radiotherapy to target the pancreatic tumor. Throughout the study, participants will be closely monitored for safety using various assessments over periods up to 40 months. Researchers will evaluate adverse effects, drug behavior in the body, and the antitumor activity of the combination treatment. Participants will undergo scheduled assessments including vital signs, laboratory tests, and imaging. The total study duration may extend for several years, with ongoing safety and efficacy evaluations.
CONDITIONS
Brief Title
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
Research Team
R
Robbin Frnka
J
Jeanne Jones
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here